Review





Similar Products

anti human vegfr2 apc  (Miltenyi Biotec)
94
Miltenyi Biotec anti human vegfr2 apc
Anti Human Vegfr2 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/CD309+(VEGFR-2)+Antibody%2C+anti-human%2C+REAfinity/pmc11981852-944-0-3
Average 94 stars, based on 1 article reviews
anti human vegfr2 apc - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
vegfr2  (MedChemExpress)
94
MedChemExpress vegfr2
Vegfr2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/VEGF-B%2C+Human/pm41956242-309-0-8
Average 94 stars, based on 1 article reviews
vegfr2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
kdr  (R&D Systems)
93
R&D Systems kdr
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Kdr, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/Human+VEGFR2%2FKDR%2FFlk-1+Antibody/bio_rxiv__64898__2026__04__14__718471-162-27-28
Average 93 stars, based on 1 article reviews
kdr - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
human vegfr2/kdr/flk-1 pe-conjugated antibody  (Bio-Techne corporation)
94
Bio-Techne corporation human vegfr2/kdr/flk-1 pe-conjugated antibody
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Human Vegfr2/Kdr/Flk 1 Pe Conjugated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/Human+VEGFR2%2FKDR%2FFlk-1+PE-conjugated+Antibody/custom%40fab357p%4010%2E1016%2Fj%2Ejvssci%2E2026%2E100410
Average 94 stars, based on 1 article reviews
human vegfr2/kdr/flk-1 pe-conjugated antibody - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
recombinant human vegfr2 fc chimera  (R&D Systems)
93
R&D Systems recombinant human vegfr2 fc chimera
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Recombinant Human Vegfr2 Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/Recombinant+Human+VEGFR2%2FKDR+Fc+Chimera+Protein/us12600769-818-2-6
Average 93 stars, based on 1 article reviews
recombinant human vegfr2 fc chimera - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
vegf r2  (R&D Systems)
94
R&D Systems vegf r2
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Vegf R2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/Recombinant+Human+VEGFR2%2FKDR+Fc+Chimera+Protein%2C+CF/us12570733-2022-0-1
Average 94 stars, based on 1 article reviews
vegf r2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
phospho vegfr2 polyclonal antibody  (R&D Systems)
93
R&D Systems phospho vegfr2 polyclonal antibody
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Phospho Vegfr2 Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/Human+Phospho-VEGFR2%2FKDR%2FFlk-1+(Y1214)+Antibody/pmc13042361-319-16-21
Average 93 stars, based on 1 article reviews
phospho vegfr2 polyclonal antibody - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
human kdr vegfr2  (OriGene)
94
OriGene human kdr vegfr2
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Human Kdr Vegfr2, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/VEGF+Receptor+2+(KDR)+(NM_002253)+Human+Recombinant+Protein/pmc12929536-196-61-62
Average 94 stars, based on 1 article reviews
human kdr vegfr2 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
rabbit anti human vegfr2 antibody  (Servicebio Inc)
86
Servicebio Inc rabbit anti human vegfr2 antibody
(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression <t>of</t> <t>HOXC9</t> and <t>KDR</t> on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).
Rabbit Anti Human Vegfr2 Antibody, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+vegfr2/anti+vegfr2/pm41525037-124-33-38
Average 86 stars, based on 1 article reviews
rabbit anti human vegfr2 antibody - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier

Image Search Results


(A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression of HOXC9 and KDR on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).

Journal: bioRxiv

Article Title: Generation of human hindlimb/genital tubercle progenitors from pluripotent stem cells

doi: 10.64898/2026.04.14.718471

Figure Lengend Snippet: (A) Schematic of the treatment conditions used to test different regimens of RA treatment during hPSC differentiation toward HGTps. (B) Heatmap of differentially expressed pLPM/HGTp, vascular/endothelial markers and posterior HOX genes from bulk RNA-seq on day 10 untreated, late RA and early RA treated cells. Expression values are shown as Z-scores across samples. (C) Immunofluorescence analysis of the expression of HOXC9 and KDR on day 10 untreated, late RA and early RA treated cells. Scale bars represent 100 µm. Image analysis of the percentage of nuclei positive for HOXC9 protein expression is also shown. Graph shows mean values ( n = 3 independent experiments) (* p<0.05, ** p<0.01, *** p<0.001, mean ±SD) (one way ANOVA and Tukey’s multiple comparison test). (D) RNA-seq timecourse analysis of the expression levels of key RA target, genital tubercle mesenchyme, vascular/endothelial, pLPM/HGTp markers. TPM is calculated and analysed using one-way ANOVA and Tukey’s test to calculate adjusted p value (* adj p<0.05, ** adj p<0.01, *** adj p<0.001, mean ±SEM).

Article Snippet: Following primary antibodies were used; TBXT (Abcam, ab209665, 1:1000), ISL1 (DSHB, 39.4D5, 1:200), HAND1 (R&D Systems, AF3168, 1:100), PITX1 (Novus Bio, NBP1-88644, 1:500), HOXC9 (Abcam, ab50839, 1:200), KDR (R&D Systems, AF357, 1:1000), TP63 (Abcam, ab124762, 1:200).

Techniques: RNA Sequencing, Expressing, Immunofluorescence, Comparison